Background: In PD-L1-negative patients with advanced non-small-cell lung cancer (NSCLC), conclusive evidence in support of specific treatments remains lacking. Objectives: The efficacy of first-line chemoimmunotherapy versus chemotherapy alone was compared. Methods: Eligible randomized studies that included patients with advanced NSCLC irrespective of PD-L1 status who were treated with chemoimmunotherapy as the first line were identified. Kaplan-Meier curves were extracted and analyzed using restricted mean survival time (RMST). Patient-level data were reconstructed from progression-free survival (PFS) graphs. A Bayesian network meta-analysis (NETMA) was carried out. Results: In five trials selected, chemoimmunotherapy regimens, compared with chemotherapy alone, resulted in an improvement in PFS without statistical significance. In the NETMA, chemoimmunotherapy was found to slightly improve PFS. Conclusion: This analysis showed that the incremental benefit of chemoimmunotherapy versus chemotherapy is limited.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Planchard D Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(4), iv192–iv237 (2018).
Medline CASGoogle Scholar
2. Socinski MA, Obasaju C, Gandara D et al. Current and emergent therapy options for advanced squamous cell lung cancer. J. Thorac. Oncol. 13(2), 165–183 (2018).
Medline CASGoogle Scholar
3. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
Medline CASGoogle Scholar
4. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255–265 (2017).
MedlineGoogle Scholar
5. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016).
Medline CASGoogle Scholar
6. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
Medline CASGoogle Scholar
7. Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018). • Of particular significance because data on progression-free survival were extracted from these trials.
Medline CASGoogle Scholar
8. West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMPOWER-130): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol. 20(7), 924–937 (2019). • Of particular significance because data on progression-free survival were extracted from these trials.
Medline CASGoogle Scholar
9. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018). • Of particular significance because data on progression-free survival were extracted from these trials.
Medline CASGoogle Scholar
10. Jotte R, Cappuzzo F, Vynnychenko I et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous nsclc (impower-131): results from a randomized Phase III trial. J. Thorac. Oncol. 15(8), 1351–1360 (2020). • Of particular significance because data on progression-free survival were extracted from these trials.
Medline CASGoogle Scholar
11. Nishio M, Barlesi F, West H et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous nsclc: results from the randomized Phase 3 IMPOWER-132 trial. J. Thorac. Oncol. 16(4), 653–664 (2021). • Of particular significance because data on progression-free survival were extracted from these trials.
Medline CASGoogle Scholar
12. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381(21), 2020–2031 (2019).
Medline CASGoogle Scholar
13. WebPlotDigitizer. https://automeris.io/WebPlotDigitizer
Google Scholar
14. Messori A. Analysis of survival curves: a compendium of methods for managing restricted mean survival time and mean lifetime survival in the context of a Bayesian network meta-analysis. Open Science Framework doi: 10.17605/OSF.IO/4MDXR (2021). https://osf.io/3g59j/ •• This reference reports the statistical and iconographic methods used in the current study.
Google Scholar
15. Messori A, Bartoli L, Chiumente M et al. The restricted mean survival time as a tool for ranking comparative outcomes in a narrative review that evaluates a network of randomized trials: an example based on PCSK9 inhibitors. Am. J. Cardiovasc. Drugs 21(3), 349–354 (2021).
Medline CASGoogle Scholar
16. Messori A. The advantages of restricted mean survival time in analysing Kaplan-Meier survival curves: analysis of 55 articles published in the last 12 months. Open Science Framework doi: 10.17605/OSF.IO/BHQNY (2020). https://osf.io/bvqnk/
Google Scholar
17. Messori A. Eight major international journals have recently published a paper to highlight the methodological advantages of the restricted mean survival time. Open Science Framework doi: 10.17605/OSF.IO/DY3UH (2020). https://osf.io/3gj96/
Google Scholar
18. Pathak R, De Lima Lopes G, Yu H et al. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: a network meta-analysis of randomized trials. Cancer 127(5), 709–719 (2021).
Medline CASGoogle Scholar
19. Herbst R, Jassem J, Abogunrin S et al. A network meta-analysis of cancer immunotherapies versus chemotherapy for first-line treatment of patients with non-small cell lung cancer and high programmed death-ligand 1 expression. Front. Oncol. 11, 676732 (2021).
MedlineGoogle Scholar
20. Rizvi NA, Cho BC, Reinmuth N et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC Phase 3 randomized clinical trial. JAMA Oncol. 6(5), 661–674 (2020).
MedlineGoogle Scholar

Vol. 14, No. 11

Supplemental Materials

Metrics

Downloaded 208 times

History

Received 30 July 2021

Accepted 20 May 2022

Published online 13 June 2022

Published in print August 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2021-0208

Author contributions

A Messori was responsible for study conception and design; L Cancanelli and D Mengato were responsible for the acquisition of data; M Rivano, L Cancanelli and D Mengato were responsible for data analysis and drafting; M Chiumente, L Di Spazio and A Messori were responsible for data quality assurance, revision of the manuscript and final approval of the version to be published.

Financial & competing interests disclosure

Marco Chiumente is a full-time employee of SIFACT. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

PDF download